Introduction The objective of this paper is to systematically review the existing evidence of
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on …

BACKGROUND The role of tiotropium for the treatment of asthma has not yet been clearly
defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium …

OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of the
addition of tiotropium to standard treatment regimens for inadequately controlled asthma …

Introduction: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has
recently been approved for use in the treatment of asthma in a number of countries …

Background Long-acting muscarinic antagonist (LAMA) tiotropium improved lung function
and reduced risks of exacerbation when added on to inhaled corticosteroids (ICS) with or …

Asthma is a chronic disease of airway inflammation with a large global burden. Despite
established, guideline‐based stepwise therapy, a significant proportion of patients remain …

Background Many patients with asthma remain symptomatic despite treatment with inhaled
corticosteroids (ICS) with or without long-acting β 2-agonists (LABAs). Tiotropium add-on to …

Objective Tiotropium is a long-acting muscarinic antagonist approved for maintenance
treatment of asthma in children, adolescents, and adults in the United States, and …

Tiotropium: a new therapeutic option in asthma. F. Novelli, F. Costa, M. Latorre, L.
Malagrinò, A. Celi, B. Vagaggini, P. Paggiaro. Although bronchial hyperresponsiveness to …

Given the high proportion of patients with asthma who remain uncontrolled despite controller
treatment, there remains a need for the development of more effective treatment options with …